arrow
W

William J. Gradishar

pennsylvania commonwealth system of higher education (pcshe)
H指数:78
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I

USP22通过mhc-i的EZH2-mediated表观遗传沉默驱动肿瘤免疫逃避和检查点阻断抵抗

2026-01-024
OA
Breast Cancer, Version 5.2025 Featured Updates to the NCCN Guidelines

Gradishar, W.J.; Moran, M.S.; Abraham, J.; Abranson, V.; Aft, R.; Agnese, D.; Allison, K.H.; Anderson, B.; Bailey, J.; Burstein, H.J.; et al. NCCN指南,乳腺癌,版本5。J. Natl. Compr. Cancer Netw. 2025, 23, 426–436. [Google Scholar] [CrossRef]

2025-11-013
PRE
Computational ranking identifies Plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis

计算排名识别出Plexin-B2在循环肿瘤细胞与单核细胞聚集中参与乳腺癌转移

2025-08-160
OA
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study

对认知行为疗法策略与健康管理内容以降低乳腺癌幸存者癌症复发恐惧的定性考察:FoRtitude研究的结果

2025-07-280
PRE
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer

MGAT1引导的复合N-糖链在CD73上调控三阴性乳腺癌的免疫逃逸

2025-04-150
OA
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

转移性乳腺癌中种族差异、ctDNA谱、靶向治疗使用及结局

2025-02-261
OA
Acceptability of the Fit2ThriveMB mHealth physical activity promotion intervention in women with metastatic breast cancer

Fit2ThriveMB移动健康身体活动促进干预措施在患有转移性乳腺癌女性中的可接受性

2025-01-060
PRE
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling

在转移性乳腺癌中整合机器学习预测的循环肿瘤细胞 (ctc) 和循环肿瘤DNA (ctDNA): 内分泌耐药分析的原理研究证明

2025-01-010
PRE
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

6th和7th晚期乳腺癌管理国际共识指南 (ABC指南6和7)

BREAST
IF7.9
2024-08-0122
OAAI
Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer

Fit2ThriveMB试点体力活动促进干预对转移性乳腺癌患者体力活动和患者报告结果的可行性和初步效果

2024-07-162
PRE
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
2024-07-050
OAAI
Breast Cancer, Version 3.2024
2024-07-0120
PRE
Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA
2024-05-020
PRE
Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer
2024-05-020
PRE
ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan
2024-05-020
PRE
Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA
2024-05-020
PRE
Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis
2024-05-020
PRE